# Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

> **NCT06433219** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 63 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Tuvusertib (M1774)
- **DRUG:** Niraparib
- **DRUG:** Lartesertib (M4076)

## Key facts

- **NCT ID:** NCT06433219
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-30
- **Primary completion:** 2025-09-29
- **Final completion:** 2026-06-26
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06433219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06433219, "Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06433219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*